Cargando…

ABCG2 in Acute Myeloid Leukemia: Old and New Perspectives

Despite recent advances, prognosis of acute myeloid leukemia (AML) remains unsatisfactory due to poor response to therapy or relapse. Among causes of resistance, over-expression of multidrug resistance (MDR) proteins represents a pivotal mechanism. ABCG2 is an efflux transporter responsible for indu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Damiani, Daniela, Tiribelli, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138346/ https://www.ncbi.nlm.nih.gov/pubmed/37108308 http://dx.doi.org/10.3390/ijms24087147

Ejemplares similares

Checkpoint Inhibitors in Acute Myeloid Leukemia
por: Damiani, Daniela, et al.
Publicado: (2023)

Present and Future Role of Immune Targets in Acute Myeloid Leukemia
por: Damiani, Daniela, et al.
Publicado: (2022)

Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center
por: Tiribelli, Mario, et al.
Publicado: (2021)

Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors
por: Damiani, Daniela, et al.
Publicado: (2015)

Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?
por: Tarantini, Francesco, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Editorial: Advances in the treatment of chronic myeloid leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2023)

TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited
por: Shin, Dong-Yeop
Publicado: (2023)

Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib
por: Loscocco, Federica, et al.
Publicado: (2021)

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment
por: Reed, Daniel R, et al.
Publicado: (2019)

Early Ophthalmological Manifestations of Acute Myeloid Leukemia: Current Perspectives
por: El Salloukh, Nasrine Anais, et al.
Publicado: (2022)

Novel Agents for Acute Myeloid Leukemia
por: Luppi, Mario, et al.
Publicado: (2018)

New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
por: Andreozzi, Fabio, et al.
Publicado: (2022)

New agents in acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2020)

Acute Myeloid Leukemia in the Elderly Patient: New Strategies
por: Thomas, Xavier
Publicado: (2015)

New Therapeutic Strategies for Adult Acute Myeloid Leukemia
por: Ishii, Hiroto, et al.
Publicado: (2022)

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

The Patient Perspective on Living with Acute Myeloid Leukemia
por: Tomaszewski, Erin L., et al.
Publicado: (2016)

New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise
por: Bohl, Stephan R., et al.
Publicado: (2019)

Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma
por: Sukowati, Caecilia HC, et al.
Publicado: (2012)

Acute Myeloid Leukemia: Is It T Time?
por: Khoud, Meriem Ben, et al.
Publicado: (2021)

Insights into the New Molecular Updates in Acute Myeloid Leukemia Pathogenesis
por: Demir, Derya
Publicado: (2023)

Early Palliative Care in Acute Myeloid Leukemia
por: Potenza, Leonardo, et al.
Publicado: (2022)

Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives
por: Talati, Chetasi, et al.
Publicado: (2018)

Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
por: Pinto-Merino, Álvaro, et al.
Publicado: (2022)

Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
por: Maucher, Marius, et al.
Publicado: (2021)

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the Elderly: Review of Literature and New Perspectives
por: Magliano, Gabriele, et al.
Publicado: (2020)

PTEN Regulates BCRP/ABCG2 and the Side Population through the PI3K/Akt Pathway in Chronic Myeloid Leukemia
por: Huang, Fang-Fang, et al.
Publicado: (2014)

Sitosterolemia: Twenty Years of Discovery of the Function of ABCG5 ABCG8
por: Williams, Kori, et al.
Publicado: (2021)

MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia
por: Trino, Stefania, et al.
Publicado: (2018)

3D structure of the transporter ABCG2—What's new?
por: Eckenstaler, Robert, et al.
Publicado: (2020)

Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2020)

Classification of acute myeloid leukemia
por: Hwang, Sang Mee
Publicado: (2020)

The beginning of a new therapeutic era in acute myeloid leukemia
por: Récher, Christian
Publicado: (2021)

Immune therapy: a new therapy for acute myeloid leukemia
por: Tian, Chen, et al.
Publicado: (2022)

New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
por: Chen, Jing, et al.
Publicado: (2020)

Correction: PTEN Regulates BCRP/ABCG2 and the Side Population through the PI3K/Akt Pathway in Chronic Myeloid Leukemia
Publicado: (2014)

Tipifarnib in the treatment of acute myeloid leukemia
por: Thomas, Xavier, et al.
Publicado: (2007)

Differentiation Therapy of Acute Myeloid Leukemia
por: Gocek, Elzbieta, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9bheoja5vi11v9j9bj20vdn44k